USD 0.18
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | 0.0% |
2020 | - CAD | 0.0% |
2019 | - CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | -100.0% |
2008 | 262.62 Thousand CAD | -6.12% |
2007 | 279.73 Thousand CAD | 7513.91% |
2006 | 3674.00 CAD | 0.0% |
2005 | - CAD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - CAD | 0.0% |
2024 Q2 | - CAD | 0.0% |
2024 Q3 | - CAD | 0.0% |
2023 FY | - CAD | 0.0% |
2023 Q3 | - CAD | 0.0% |
2023 Q2 | - CAD | 0.0% |
2023 Q4 | - CAD | 0.0% |
2023 Q1 | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2022 Q1 | - CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
2022 Q2 | - CAD | 0.0% |
2022 FY | - CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2021 Q1 | - CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2021 Q3 | - CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2020 Q2 | - CAD | 0.0% |
2020 Q4 | - CAD | 0.0% |
2020 FY | - CAD | 0.0% |
2020 Q1 | - CAD | 0.0% |
2020 Q3 | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2019 Q4 | - CAD | 0.0% |
2019 FY | - CAD | 0.0% |
2019 Q3 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2010 Q1 | - CAD | 100.0% |
2010 FY | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2009 FY | - CAD | -100.0% |
2009 Q2 | 1329.00 CAD | -78.35% |
2009 Q4 | -7960.00 CAD | -1714.6% |
2009 Q3 | 493.00 CAD | -62.9% |
2009 Q1 | 6138.00 CAD | -65.39% |
2008 Q2 | 74.41 Thousand CAD | -43.44% |
2008 FY | 262.62 Thousand CAD | -6.12% |
2008 Q3 | 38.92 Thousand CAD | -47.7% |
2008 Q4 | 17.73 Thousand CAD | -54.43% |
2008 Q1 | 131.55 Thousand CAD | 58.15% |
2007 FY | 279.73 Thousand CAD | 7513.91% |
2007 Q1 | 18.29 Thousand CAD | 0.0% |
2007 Q4 | 83.18 Thousand CAD | -13.34% |
2007 Q3 | 95.98 Thousand CAD | 16.68% |
2007 Q2 | 82.26 Thousand CAD | 349.58% |
2006 Q2 | - CAD | 0.0% |
2006 Q3 | - CAD | 0.0% |
2006 Q4 | - CAD | 0.0% |
2006 FY | 3674.00 CAD | 0.0% |
2006 Q1 | - CAD | 0.0% |
2005 FY | - CAD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
American Bio Medica Corporation | 913 Thousand USD | 100.0% |
Arrayit Corporation | 4.37 Million USD | 100.0% |
Atlantic International Corp. | - USD | NaN% |
Biocept, Inc. | 25.85 Million USD | 100.0% |
Bioqual, Inc. | 58.59 Million USD | 100.0% |
CardioGenics Holdings Inc | - USD | NaN% |
DermTech, Inc. | 15.29 Million USD | 100.0% |
Global WholeHealth Partners Corporation | - USD | NaN% |
Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 100.0% |
HTG Molecular Diagnostics, Inc. | 6.36 Million USD | 100.0% |
iMD Companies, Inc. | - USD | NaN% |
IDenta Corp. | 1.05 Million USD | 100.0% |
Interpace Biosciences, Inc. | 40.21 Million USD | 100.0% |
Integrative Health Technologies, Inc. | 447.49 Thousand USD | 100.0% |
InVitro International | 792.62 Thousand USD | 100.0% |
Lumos Diagnostics Holdings Limited | 11.13 Million USD | 100.0% |
Many Bright Ideas Technologies Inc. | - USD | NaN% |
Medical Imaging Corp. | 7.22 Million USD | 100.0% |
NovelStem International Corp. | 12 Thousand USD | 100.0% |
Optigenex Inc. | 465.97 Thousand USD | 100.0% |
PharmChem, Inc. | 6.01 Million USD | 100.0% |
Proteome Sciences plc | 6.4 Million USD | 100.0% |
Response Genetics, Inc | 18.04 Million USD | 100.0% |
Rennova Health, Inc. | 13.03 Million USD | 100.0% |
RushNet, Inc. | 1.78 Million USD | 100.0% |
ScreenPro Security Inc. | 1.91 Million USD | 100.0% |
Stella Diagnostics Inc. | - USD | NaN% |
StageZero Life Sciences Ltd. | 3.79 Million USD | 100.0% |
Todos Medical Ltd. | 7.69 Million USD | 100.0% |